PLA-695 clinical trials
Also written PLA-695.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses PLA-695 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PLA-695
- 3
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses PLA-695 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and NaproxenCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00366262Written as PLA-695How we know
- A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The KneeTerminatedPhase 2Wyeth is now a wholly owned subsidiary of PfizerNCT00396955Written as PLA-695How we know
- Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid ArthritisCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00440492Written as PLA-695How we know